Q-omics provides the consensus-scored PRH1 profile across patient tissues and cancer cell-line models. PRH1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PRH1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PRH1 RNA expression shows 17,594 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, HNSC, and UVM as cancer lineages where PRH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRH1 survival associations across molecular data types. PRH1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRH1 RNA expression–survival associations across cancer types. High PRH1 expression shows unfavorable associations in COAD, STAD, KIRC, DLBC and UVM, but favorable associations in UCEC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for PRH1 RNA expression.
This table summarizes PRH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRH1 shows lower tumor expression in HNSC, KICH, BRCA and THCA and higher tumor expression in PAAD and STAD. The HNSC box plot shows higher PRH1 RNA expression in normal versus tumor tissue (log2 FC = −2.130, t-test p < 0.001).
This table shows molecular features associated with PRH1 in patient tissues and cancer cell lines. In patient samples, PRH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OESOPHAGUS.
